Antifungal susceptibility profiles of bloodstream yeast isolates by sensititre yeastone over nine years at a large Italian teaching hospital

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3944-3955

  Posteraro, Brunella ^a   Spanu, Teresa ^a   Fiori, Barbara ^a   De Maio, Flavio ^a   De Carolis, Elena ^a   Giaquinto, Alessia ^a   Prete, Valentina ^a   De Angelis, Giulia ^a   Torelli, Riccardo ^a   D'Inzeo, Tiziana ^a   Vella, Antonietta ^a   De Luca, Alessio ^a   Tumbarello, Mario ^a   Ricciardi, Walter ^a   Sanguinetti, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CLINICAL LABORATORY; CRYPTOCOCCUS NEOFORMANS; DRUG MECHANISM; FEMALE; FUNGUS ISOLATION; HOSPITAL LABORATORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHODOTORULA; SENSITITRE YEASTONE; TEACHING HOSPITAL; WILD TYPE; CROSS INFECTION; DRUG EFFECTS; ITALY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOSIS; VERY ELDERLY; YEAST;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FEMALE; HOSPITALS, TEACHING; HUMANS; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; YEASTS;

EID: 84931275543     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00285-15     Document Type: Article

References (50)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
2. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):S19-S37. http://dx.doi.org/10.1111/1469-0691.12039.
3. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):S53-S67. http://dx.doi.org/10.1111/1469-0691.12041.
4. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 20(Suppl 3):S76-S98. http://dx.doi.org/10.1111/1469-0691.12360.
5. Türel O. 2011. Newer antifungal agents. Expert Rev Anti Infect Ther 9:325-338. http://dx.doi.org/10.1586/eri.10.163.
6. Fera MT, La Camera E, De Sarro A. 2009. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 7:981-998. http://dx.doi.org/10.1586/eri.09.67.
7. Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, de Gaetano Donati K, Fadda G, Cauda R, Posteraro B. 2008. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 62:1379-1385. http://dx.doi.org/10.1093/jac/dkn381.
8. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55:532-538. http://dx.doi.org/10.1128/AAC.01128-10.
9. Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. 2012. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 56:3239-3243. http://dx.doi.org/10.1128/AAC.00019-12.
10. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B, Rosenvinge FS, Røder BL, Schønheyder HC. 2013. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 19:E343-E353. http://dx.doi.org/10.1111/1469-0691.12212.
11. Arendrup MC. 2014. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 20(Suppl 6):S42-S48. http://dx.doi.org/10.1111/1469-0691.12513.
12. Cuenca-Estrella M. 2014. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. Clin Microbiol Infect 20(Suppl 6):S54-S59. http://dx.doi.org/10.1111/1469-0691.12495.
13. Guinea J. 2014. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 20(Suppl 6):S5-S10. http://dx.doi.org/10.1111/1469-0691.12539.
14. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. 2012. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 55:1352-1361. http://dx.doi.org/10.1093/cid/cis697.
15. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
16. Cuenca-Estrella M, Rodriguez-Tudela JL. 2010. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther 8:267-276. http://dx.doi.org/10.1586/eri.10.2.
17. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(1 Suppl):S3-S13. http://dx.doi.org/10.1016/j.amjmed.2011.11.001.
18. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 2014. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 58:1897-1906. http://dx.doi.org/10.1128/AAC.02163-13.
19. Posteraro B, Sanguinetti M. 2014. The future of fungal susceptibility testing. Future Microbiol 9:947-967. http://dx.doi.org/10.2217/fmb.14.55.
20. Huang YT, Liu CY, Liao CH, Chung KP, Sheng WH, Hsueh PR. 2014. Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010. Antimicrob Agents Chemother 58:3814-3819. http://dx.doi.org/10.1128/AAC.01035-13.
21. van Hal SJ, Chen SC, Sorrell TC, Ellis DH, Slavin M, Marriott DM. 2014. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. J Antimicrob Chemother 69:2210-2214. http://dx.doi.org/10.1093/jac/dku124.
22. Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G, Fadda G, Posteraro B. 2007. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 45:1343-1346. http://dx.doi.org/10.1128/JCM.02469-06.
23. Posteraro B, De Carolis E, Vella A, Sanguinetti M. 2013. MALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond. Expert Rev Proteomics 10:151-164. http://dx.doi.org/10.1586/epr.13.8.
24. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. 2012. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 174:259-271. http://dx.doi.org/10.1007/s11046-012-9551-x.
25. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13:180-195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
26. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 70:330-343. http://dx.doi.org/10.1016/j.diagmicrobio.2011.03.002.
27. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14:164-176. http://dx.doi.org/10.1016/j.drup.2011.01.004.
28. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50:2846-2856. http://dx.doi.org/10.1128/JCM.00937-12.
30. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
31. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother 56:6304-6309. http://dx.doi.org/10.1128/AAC.00813-12.
32. Perlin DS. 2011. Current perspectives on echinocandin class drugs. Future Microbiol 6:441-457. http://dx.doi.org/10.2217/fmb.11.19.
33. Lai CC, Chu CC, Wang CY, Tsai HY, Cheng A, Lee YC, Huang YT, Liao CH, Hsueh PR. 2012. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents 40:349-353. http://dx.doi.org/10.1016/j.ijantimicag.2012.05.024.
34. Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. 2013. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 68:438-443. http://dx.doi.org/10.1093/jac/dks388.
35. Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D. 2014. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis 79:205-208. http://dx.doi.org/10.1016/j.diagmicrobio.2014.02.016.
36. Miceli MH, Díaz JA, Lee SA. 2011. Emerging opportunistic yeast infections. Lancet Infect Dis 11:142-151. http://dx.doi.org/10.1016/S1473-3099(10)70218-8.
37. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA. 2013. Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol 51:117-124. http://dx.doi.org/10.1128/JCM.01686-12.
38. Marcos-Zambrano LJ, Escribano P, Sánchez C, Muñoz P, Bouza E, Guinea J. 2014. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565-4572. http://dx.doi.org/10.1128/AAC.02670-14.
39. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE. 2014. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 9:e101510. http://dx.doi.org/10.1371/journal.pone.0101510.
40. Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, Chen SL, Yan Y, Kang M, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Kong F, Xu YC. 2015. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 70:802-810. http://dx.doi.org/10.1093/jac/dku460.
41. Cantón E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J, Martínez-Alarcón J, Fontanals D, Gomila-Sard B, Buendía B, Torroba L, Ayats J, Bratos A, Sánchez-Reus F, Fernández-Natal I, FUNGEMYCA Study Group. 2012. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol 50:3921-3926. http://dx.doi.org/10.1128/JCM.01730-12.
42. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57:5836-5842. http://dx.doi.org/10.1128/AAC.01519-13.
43. Pfaller MA, Messer SA, Diekema DJ, Jones RN, Castanheira M. 2014. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol 52:108-114. http://dx.doi.org/10.1128/JCM.02481-13.
44. Pfaller MA, Diekema DJ, Jones RN, Castanheira M. 2014. Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol 52:3223-3229. http://dx.doi.org/10.1128/JCM.00782-14.
45. Guinea J, Zaragoza Ó, Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M, CANDIPOP Project, GEIH-GEMICOMED (SEIMC), REIPI. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 58:1529-1537. http://dx.doi.org/10.1128/AAC.02155-13.
46. Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58:2006-2012. http://dx.doi.org/10.1128/AAC.02615-13.
47. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, Diaz-Martin A, Luzzati R, Rosin C, Lagunes L, Trecarichi EM, Sanguinetti M, Posteraro B, Garnacho-Montero J, Sartor A, Rello J, Rocca GD, Antonelli M, Tumbarello M. 2014. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 40:839-845. http://dx.doi.org/10.1007/s00134-014-3310-z.
48. Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A, Bernal-Martinez L, Cuesta I, Buitrago MJ, Rodriguez-Tudela JL. 2010. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J Clin Microbiol 48:1782-1786. http://dx.doi.org/10.1128/JCM.02316-09.
49. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R. 2012. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn Microbiol Infect Dis 73:365-368. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.008.
50. Cantón E, Pemán J, Iñiguez C, Hervás D, Lopez-Hontangas JL, Pina-Vaz C, Camarena JJ, Campos-Herrero I, García-García I, García-Tapia AM, Guna R, Merino P, Pérez del Molino L, Rubio C, Suárez A, FUNGEMYCA Study Group. 2013. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol 51:2691-2695. http://dx.doi.org/10.1128/JCM.01230-13.